Type 2 diabetes (T2D) is a chronic disorder with a growing prevalence. The progression and incidence of diabetes-related complications can be reduced with improved glycemic control. Dapagliflozin is a highly selectively SGLT2 inhibitor through which reabsorption of glucose into the bloodstream is diminished and promotes glucose filtration through the kidneys. The addition of dapagliflozin to therapies of metformin, glimepiride, sitagliptin, and insulin demonstrated positive reductions in HbA1c, FPG, and body weight compared with placebo. SGLT2 inhibitors have favorable cardiovascular effects predominantly in patients with type 2 diabetes and established cardiovascular disease; they have also been shown to delay kidney disease progression.